DKSH Supports Growth for Vitabiotics in Hong Kong and Malaysia

DKSH, the leading Market Expansion Services provider with a focus on Asia, and Vitabiotics, Britain’s largest and fastest growing major vitamin supplement company, has signed an agreement to expand the firm’s product range into Hong Kong and Malaysia.

BANGKOK, April 8, 2015 /PRNewswire/ — DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia, will provide marketing, sales, distribution, logistics and regulatory services for Vitabiotics in Hong Kong and Malaysia. The agreement is an extension of a collaboration that started in Taiwan in 2011.

DKSH will broaden Vitabiotics’ already established market position and product range in Hong Kong on offer by leveraging its reach and deepening distribution to more pharmacy outlets. The Vitabiotics range is also undergoing approval by authorities in Malaysia.

According to a recent study by Roland Berger Strategy Consultants, the Market Expansion Services market for over-the-counter healthcare products in Hong Kong is expected to grow by 5-6% annually between 2014 and 2019. Malaysia is expected to see a slightly higher growth rate of 6-7% growth per year over the same period.

“The diverse Asian market shows excellent long term growth potential for Vitabiotics’ products. Working with our regional partner DKSH allows us to accelerate our growth and enter new strategic markets at the same time. While we can focus on our core strengths, DKSH’s strong commitment to compliance and governance gives us the security that the expansion of our business is in safe hands,” said Robert Taylor, Vice President, Vitabiotics.

“Our regional reach and integrated services give Vitabiotics the convenience of working with one strategic partner across multiple markets. With the insights and commercial capabilities of our local experts and our broad capillary distribution, we are confident to spur further growth for Vitabiotics in Asia,” said Andrew Frye, Head of Business Healthcare, DKSH.

The agreement will strengthen DKSH’s market position in Asia over time.

About Vitabiotics

Vitabiotics has pioneered advances in nutritional healthcare for 45 years, a British company committed to human health and research. As the UK’s No.1 vitamin company, Vitabiotics has created a unique portfolio of products at the forefront of scientific developments in key sectors, with no fewer than 8 brands in the top 18 VMS brands in the UK, including Pregnacare, Osteocare, Wellman and Wellwoman. Vitabiotics is widely acknowledged as leaders in innovation and in 2013 became the first vitamin company to receive the Queen’s Award for Innovation, awarded for its ground breaking clinical research.

As the fastest growing major vitamin company in the UK, Vitabiotics exports to over 100 countries, and has twice received the Queen’s Awards for International Trade. Designed to provide maximum efficacy by supporting the human body in its own natural processes, each product is developed using the latest research available and is produced to the highest pharmaceutical standards.

About DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term “Market Expansion Services” suggests, DKSH helps other companies and brands to grow their business in new or existing markets.

Publicly listed on the SIX Swiss Exchange since March 2012, DKSH is a global company headquartered in Zurich. With 750 business locations in 35 countries — 720 of them in Asia — and 27,600 specialized staff, DKSH generated net sales of CHF 9.8 billion in 2014.

In 2015, DKSH celebrates its 150th anniversary. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia, and is deeply rooted in communities and businesses across Asia Pacific.

DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration, regulatory services, market entry studies, importation, customs clearance, marketing and sales, physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include pharmaceuticals, consumer health and over-the-counter (OTC) products, as well as medical devices. With 150 business locations in 14 countries and around 9,200 specialized staff, Business Unit Healthcare serves over 150,000 customers and generated net sales of around CHF 4.5 billion in 2014.

Novogen Engages Leading US Investor Relations Firm

SYDNEY, April 2, 2015 /PRNewswire/ — Novogen Ltd (ASX:NRT NASDAQ:NVGN) today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company’s investor-awareness program in the US. PCG will be using their expertise in creating awareness and establishing key relationships within the US investment community via their targeted outreach campaign.

Dr Graham Kelly said: “The investment community has reacted positively in recent times to the Company’s extensive drug discovery program and with significant growth in activity ahead in the short-term, we felt it was timely to appoint an advisory firm to build on that momentum and communicate our activities to the market to maximise shareholder value.  Showcasing the Company to the wholesale investment community is a key part of our strategy to bring new investors into the stock through on-market buying. We look forward to working with the PCG team.”

Jeff Ramson, Founder and CEO of PCG stated, “We are excited to work with the entire team at Novogen.  We have extensive experience with Australian emerging growth companies that have stakeholders on several continents.  We look forward to communicating the Novogen story to a larger group of US investors, who need to learn about their drug technology platforms and how management will execute the Company’s strategy in the short and long term. We look forward to the partnership.”


Founded in 2008, PCG Advisory Group is dedicated to the delivery of top tier capital markets advisory services, strategic investor relations, tactical digital and social media communications and cutting edge media and public relations for public and privately held companies. The team at PCG has extensive experience with life sciences and healthcare, high technology, metals and mining, financial services and emerging growth companies from around the globe.

PCG’s Capital Markets Advisory Services include overall investor relations’ strategy development to increase and leverage investor awareness, visibility and credibility. PCG’s Social and Digital Media services include leveraging social and professional digital media sites to effectively and accurately communicate client stories. As an aggregation, distribution, and engagement platform, PCG reaches thousands of individual, retail, institutional investors, bankers and analysts using proprietary techniques, search engine optimization, online marketing, website development and our proprietary and extensive distribution network. PCG’s Media and Public Relations services are a strategic and integral component of all Corporate Communications. The media and public relations team works with print, broadcast, online news sites and bloggers to communicate the best client story at the right time. PCG also actively assists clients during the pre- and post-IPO process as well as through mergers, acquisitions, uplistings, and or a potential crisis. Communicating the client’s story accurately and effectively is tantamount to maximizing exposure to its current and potential stakeholders.

About Novogen Limited

Novogen is a public, drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’).  The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs).  SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells.  The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubule drugs, result in comprehensive and fatal destruction of the cancer cell’s cytoskeleton.  Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our websites

For more information please contact:

Corporate Contact

Dr. Graham Kelly

Executive Chairman & CEO

Novogen Group           

+61 (0) 2 9472 4100

Media Enquiries

Cristyn Humphreys

Chief Operating Officer

Novogen Group

+61 (0) 2 9472 4111

Hainan Province, Hengda Health and Korean Yuanchen Signs Strategic Cooperation Agreement

BOAO, China, March 29, 2015 /PRNewswire/ — In the evening on March 29, Hong Kong listed company New Media (HK.708) (to be changed into Hengda Health Industry Co., Ltd.) announced that it has signed a strategic investment cooperation framework agreement with the Management Committee of the pioneer district of the international medical tourism in Lecheng, Boao, Hainan Province; and Korean Yuanchen Medical Cosmetology Group on March 28 to establish an international medical cosmetology and anti-aging center at the above mentioned pioneer district. An original report from Sina Leju follows.

Three parties has completed the signing ceremony at the Boao Health Forum on March 28, including Lu Junhua, vice-governor of Hainan Province; Tan Zhaohui, executive vice president of Hengda Group and Board chairman of New Media (Hengda Health); and Piao Yuanchen, president of Korean Yuanchen Medical Cosmetology Group.

The “Internet + Health and medical treatment” is now perceived as the most attractive direction and the hottest topic at this Forum. The leading enterprises mainly include Ali Health, Hengda Health and so on. Ali Health, formed by Ali Group through the purchasing of CITIC 21 Century, has a current total market value of HKD 55.4 billion. Hengda Health is formed by Hengda Group through an acquisition of New Media that has just completed. The company has also completed the change in board of directors and is currently with a current total market value of HKD 5.8 billion. These two companies are the industrial leaders, both of which are listed in Hong Kong.

According to the agreement, New Media (Hengda Health) will cooperate with Korean Yuanchen to invest in the construction of the hospital with integration of medial plastic surgery, beauty and anti-aging health, creating a high-end international Beauty Surgery Hospital with advanced technology, professional teams and modern management and plans to use the information modes such as highly efficient and accurate big data, mobile internet, etc. to provide a one-stop service for health and medical tourists.

Korean Yuanchen is the earliest and largest medial beauty group in South Korea. Lexing District in Boao is the first pioneer district of the international medial tourism approved by the State Council and has won 9 national preferential policies such as accelerating the registration and approval process of medical apparatus and instruments, drugs import, etc. According to the authoritative report, it is estimated that the total scale of the health service industry will reach RMB 8,000 billion in China in 2020. Thus, the industrial prospect is bright.

China’s BeiGene Selects SAFC CHOZN® Platform for Commercial Drug Development

ST. LOUIS, March 11, 2015 /PRNewswire/ — Sigma-Aldrich® Corporation (NASDAQ: SIAL) today announced that SAFC® Commercial (, its custom manufacturing services business unit, entered a commercial sales and service contract with leading Chinese biopharmaceutical company, BeiGene ( Located in Beijing, the innovative oncology company purchased SAFC’s off-the-shelf, turnkey CHOZN cell line production platform and cell line engineering services to support discovery and commercial development of BeiGene’s targeted oncology drug.

“The CHOZN Platform offers us a great deal of value through the ability to maximize the production of monoclonal antibodies and other recombinant-proteins used in our targeted oncology treatments,” commented Dr. Kang Li, Head of Biologics from BeiGene. “Time is of the essence for every project. Our goal in selecting the CHOZN Platform and services was to shorten bioproduction times in early development and to obtain a manufacturing clone quickly with the highest protein quality specifications.”

“Following last year’s first commercial placement of the GS-/- CHO cell line in the Asian markets, SAFC is seeing significant interest in using our CHOZN recombinant cell line development platforms in the region,” said Kevin Gutshall, Global Sr. Manager of the CHOZN Platform for SAFC. “The CHOZN Platform supports efficient innovation and the highest quality therapeutics. It offers a turnkey solution that is unmatched in the industry. Users simply identify and clone the genes for their therapeutic protein of interest into the CHOZN expression vector, and then employ the traditional cell line development strategies of transfection, selection and cloning. The CHOZN Platform is designed to deliver a robust producing clone – ready for manufacturing.”

Enabled by Sigma-Aldrich’s, CompoZr® Zinc Finger Nuclease (ZFN) gene editing technology, the first commercially available glutamine synthetase (GS) knockout CHO line was brought to market in 2011. The full CHOZN Platform includes the CHOZN GS-/- CHO cell line and an optimized set of cGMP-produced and chemically defined media and feeds. In addition to the cell line, media, and feed, SAFC provides extensive user support which includes working with customer on protocols – from transfection through to scale-up in bioreactors, as well as comprehensive cell-line safety testing and development history.

For more information about the CHOZN Platform, visit:

©2015 Sigma-Aldrich Co. LLC. All rights reserved. Sigma-Aldrich and SAFC are trademarks of Sigma-Aldrich Co. LLC or its affiliates, registered in the U.S. and other countries.

Green Cross Expands Cell Therapy Business in China

YONGIN, South Korea, March 11, 2015 /PRNewswire/ — Green Cross, a South Korean biopharmaceutical company, today announced that it had signed MOU on the 6th of March with the Guizhou provincial government of China for the investment in the cell therapy sector in China.

Under the MOU, the company will build a cell therapy facility in the southwestern Chinese province in order to produce and distribute cell therapy products in China. The provincial government will provide administrative supports and human resources for the new facility.

Green Cross has a robust and growing portfolio of approved and investigational cell therapy projects including T cell, NK cell, dendritic cell and stem cells. Cell therapies are an increasingly significant tool in the treatment of serious diseases. Cell-based therapy industry continued to show promising overall growth and even greater growth expected to follow.

“Our investment reflects the strength of our business and the increasingly important role that cell therapy will play in Green Cross’ future,” said BG Rhee, President of Green Cross Holdings. “Over the last 20 years, Green Cross has maintained a significant manufacturing facility and sales forces for plasma fractionation business in China, and we look forward to building on that legacy through this business expansion.”

The Chinese pharmaceutical market has emerged as a major driver of revenue growth for global pharmaceutical companies, according to a report from McKinsey & Company. The report shows that China’s pharmaceutical market has grown at a rapid 21% compound annual rate over the years. In a recent forecast, China’s pharmaceutical market is projected to continue to grow at around 17% annually and likely to become the second-largest pharmaceutical market by 2020.

About Green Cross

Green Cross provides total healthcare solutions that address the evolving needs of human health. Headquartered in Yongin, South Korea, Green Cross specialises in the development and manufacturing of plasma-derivatives, vaccines and recombinant proteins.

This release includes forward-looking statements concerning the company’s business expansion plan in China. The statements are based on assumptions about many important factors. The company does not undertake to update its forward-looking statements.

Pegasus diversifies into advertising business and publication of high-end magazine “Platinum of UnionPay”

HONG KONG, March 9, 2015 /PRNewswire/ — The Board of Directors of Pegasus Entertainment Holdings Limited (“Pegasus” or the “Company”, stock code: 1326) announced on 6 March 2015 that the Company entered into a conditional agreement on the same date, to acquire the entire interest in Chili Advertising & Promotions Limited (the “Target Company”), which includes an indirect 70% interest in Chili Platinum Advertising and Magazine Publishing Limited (“Chili Platinum”), at a total consideration of HK$68.0 million. Chili Platinum is a company principally engaged in the publication of the luxury lifestyle magazine “Platinum of UnionPay”.

The consideration represents a discount of approximately 18% to the preliminary valuation of the Target Group issued by an independent valuer, which is not less than HK$82.6 million; and will be settled partly by cash and partly by the Company’s issue of consideration shares at HK$1.26 per share.

“Platinum of UnionPay” is a magazine which will be provided on a complementary basis to selected premium level cardholders of UnionPay and the target audience group covers the high-end consumer market in mainland China, Hong Kong and Macau. The magazine features a wide range of contents on luxurious lifestyle related products and services, ranging from fashion, jewellery, entertainment, food and restaurants, leisure, to art and culture. The magazine is currently distributed to various high-end private clubs, golf clubs and hotels, and also with selected contents distributed online through a number of digital media, in order to successfully capture the maximum number of targeted readership base.

The Directors are optimistic about the future development of printed and digital media advertising in the China market. In view of the growing consumption of luxury products and services in China, more international luxury brands are strengthening their foothold in China hence encouraging the advertising market for high-end goods. Given the principal target audience of “Platinum of UnionPay” magazines are high net worth individuals and other elite groups in China, who are the selected premium level cardholders of UnionPay with high disposable income, the Company is of the view that this acquisition is able to offer Pegasus the access to an established and considerable high-spending readership base for marketing purposes and therefore enables it to secure a strong competitive advantage within the industry.

Mr. Wong Pak Ming, Chairman of Pegasus, says, “By diversifying the Company’s platform into printed and digital media business, we will create synergy with our existing core business of film production and distribution by providing an additional solid marketing channel in China. That will also give Pegasus a high degree of control on the marketing campaign of our productions and to further expand our potential audiences to the high-end consumer market of China. Since the Target Company has extensive experience in the provision of film advertising and promotion services, we believe this acquisition will allow us to develop a professional in-house advertising and promotion team, which will benefit Pegasus in terms of providing flexibility to formulate and fine-tune our advertising and promotion strategies. This is an important step towards our expansion into a diversified cultural business.”

About Pegasus Entertainment Holdings Limited

Pegasus Entertainment Holdings Limited, as a diversified cultural business group, is principally engaged in the business of films and television series production, distribution, licensing of film rights, film exhibition and post-production.

About UnionPay

According to its corporate website, UnionPay, which is headquartered in China, has about 400 associate members worldwide, with its cards accepted in 150 countries and regions outside China. UnionPay has issued over 4.6 billion bank cards globally. According to its transaction data released in January 2015, UnionPay’s global network processed transactions with a total volume of RMB41 trillion in 2014, representing a year-on-year increase of 27.3%.

For further details, please refer to the announcement on HKEX website:

Omnicell, Inc. Signs Agreement to Acquire Germany-based Pharmacy Automation Provider, MACH4 Pharma Systems

— Addition of Robotic Pharmacy Automation Solutions for Hospital and Retail Pharmacies to Expand Omnicell International Growth

MOUNTAIN VIEW, Calif., Feb. 27, 2015 /PRNewswire/ — Omnicell, Inc. (OMCL), a leading provider of medication and supply management solutions to healthcare systems and pharmacies, today announced that it has signed an agreement to purchase MACH4 Pharma Systems, based in Bochum, Germany. The closing of the acquisition is subject to certain closing conditions set forth in the definitive purchase agreement. When and if the acquisition is finalized, the combination of Omnicell and MACH4 will create a comprehensive automated medication management offering for hospital and retail pharmacies throughout Europe and emerging markets internationally.

Logo –

MACH4 Pharma Systems is a provider of highly automated medication management systems to a base of over 1,000 retail and hospital pharmacy customers primarily in Europe, with additional installations in China and the Middle East.

MACH4’s modular robotic solutions for dispensing medications in original manufacturers’ packages enable the company to serve the needs of a broad spectrum of pharmacy customers, from large hospital systems to local retailers. The flexible design of MACH4 systems provides both the chaotic method of storage and retrieval that optimizes for high capacity storage in the minimum amount of physical space, and the channel method of storage and retrieval that optimizes for speed of delivery. MACH4 systems are uniquely configurable to suit each specific customer’s needs. MACH4 systems complement unique capabilities of Omnicell dispensing systems to handle medications in original manufacturers’ packages. Omnicell expects to realize expanded market opportunities as each company’s solutions are introduced to the other’s customer base.

“Omnicell is committed to providing a complete set of pharmacy automation solutions that increases efficiencies and promotes patient safety in hospital, long term care and retail settings, and to taking our global presence to a new level,” said Randall Lipps, chairman, president and CEO of Omnicell. “With MACH4, the expanded Omnicell portfolio will include innovative solutions that span robotic medication management systems, automated dispensing cabinets and medication adherence technology to meet the unique demands of our growing base of customers worldwide to provide services across the continuum of care.”

The MACH4 Pharma Systems acquisition is a continuation of Omnicell’s expansion into markets outside the United States, including the recent purchase of UK-based medication adherence packaging leader Surgichem Limited. Omnicell expects to accelerate its international growth by integrating MACH4’s high-volume medication management technology with Omnicell automated dispensing systems in the markets Omnicell presently serves, while also expanding its opportunities through MACH4’s direct presence in Germany and France.

“I expect that joining the Omnicell family will be welcome news to our customers who have come to trust MACH4’s mission to make medication management as efficient as possible in any setting,” said Holger Wallat, co-founder and CEO of MACH4. “Omnicell and MACH4 share that passion with very complementary solutions. For example, our box and blister pack management customers should benefit from Omnicell automatic dispensing cabinets that are uniquely capable of managing hospital workflows for drugs in the manufacturer’s original packaging,” he said.

Omnicell expects the acquisition to close in the first or second quarter of 2015, provided certain closing conditions are satisfied. Assuming an April 1, 2015 close, Omnicell expects 2015 revenue contribution from MACH4 will be between $12 and $15 million and Non-GAAP earnings per share dilution of approximately $0.04 as the companies are integrated. Omnicell expects the acquisition to become accretive during 2016. As a result, Omnicell financial guidance for 2015 is adjusted to include the expected results from MACH4 following the acquisition. Revenue for 2015 was previously expected to be between $480 and $490 million and is now expected to be between $492 and $505 million, an increase of 12% to 15% over 2014. Non-GAAP earnings per share were previously expected to be between $1.35 and $1.40 and are now expected to be between $1.31 and $1.36. Omnicell previously expected 2015 product bookings to be between $390 and $405 million and now expects product bookings between $398 and $416 million with the inclusion of MACH4.

About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new efficiencies to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire healthcare continuum  from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.

More than 3,000 customers worldwide have utilized Omnicell Automation and Analytics solutions to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Medication Adherence solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions to help reduce costly hospital readmissions. In addition, these solutions enable approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.

For more information about Omnicell, Inc. please visit

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the anticipated consummation of the acquisition of MACH4 Pharma Systems and the benefits thereof, including Omnicell’s expectations of future revenue, bookings and earnings, anticipated integration costs, and the combined company’s ability to help reduce medication errors and lower healthcare costs and other statements that are not historical facts. These forward-looking statements are based on Omnicell’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Omnicell’s ability to complete the acquisition on the proposed terms and schedule, including risks and uncertainties related to the satisfaction of closing conditions, including, but not limited to risks associated with business combination transactions, such as the risk that acquired business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; risks related to future opportunities and plans for the combined company, including the reaction of the combined company’s customers and potential customers, the perceived complementary nature of the combined company’s products and solutions, uncertainty of the expected financial performance, market opportunities and results of the combined company following completion of the proposed acquisition; and the possibility that if Omnicell does not achieve the perceived benefits of the proposed acquisition of MACH4 as rapidly or to the extent anticipated by financial analysts or investors, the market price of Omnicell stock could decline; as well as other risks related Omnicell’s business, and those other risks detailed from time to time under the caption “Risk Factors” and elsewhere in Omnicell’s SEC filings and reports, including in the Annual Report on Form 10-K for the year ended December 31, 2013 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Omnicell undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.


HOOQ, Asia’s Video-on-Demand Service, Debuts in the Philippines in Partnership With Globe Telecom

HOOQ offers over 10,000 blockbuster movies & TV series

MANILA, Philippines, Feb. 9, 2015 /PRNewswire/ — Just one week after its establishment, HOOQ, Asia’s video-on-demand service, announced that it will kick off in the Philippines from late February in partnership with Globe Telecom.

Filipinos first in Asia to get access to extensive Hollywood and local content with Globe Telecom and HOOQ

Filipinos first in Asia to get access to extensive Hollywood and local content with Globe Telecom and HOOQ

HOOQ, a start-up joint venture between Singtel, Sony Pictures Television and Warner Bros. Entertainment, will enable customers of Globe Telecom to enjoy unlimited online streaming access and an offline viewing option to top Hollywood and Filipino movie and television content, via any device including computers, smartphones and tablets.

Extensive Hollywood and local content

Filipinos can look forward to more than 10,000 movies and television episodes and TV shows including titles from partners Sony and Warner Bros. Customers can watch Hollywood movies such as Harry Potter, Spider-Man and Inception, while enjoying popular TV series such as Gossip Girl, Friends and Smallville.

Local film and TV content will also be available through partnerships with the country’s top studios, such as GMA, Viva Communications, Regal Entertainment, and ABS-CBN.  Customers can watch local high-grossing films such as Metro Manila, A Secret Affair, Shake Rattle and Roll and Ang Tanging Ina, as well as classics including Dyesebel, Bagets and Bituing Walang Ningning. Highly-rated TV shows like My Husband’s Lover, Mulawin, Tayong Dalawa and Mara Clara will also be available anytime and anywhere.

“Across the emerging economies, people have amazing stories and love stories. However, a few billion people have no quality way of seeing the best stories from Hollywood or their local market.  HOOQ will change that.  HOOQ will change the way people in emerging markets consume and enjoy entertainment,” said HOOQ Chief Executive Officer, Mr. Peter G. Bithos. “The Philippines is a natural first market for us. Filipinos’ dual love of local and Hollywood content combined with their  digital savviness makes the Philippines a perfect place for us to start,” he added.

The former Globe Telecom Chief Operating Advisor, Mr Bithos also announced its first distribution partnership. “Our partnership with Globe Telecom, the leader in digital partnerships in the Philippines, helps us bring Philippine customers a premium video service and new form of entertainment that combines the best of Hollywood, Asian and Philippine video content across all devices,” Mr Bithos said.

Globe Telecom’s customers first to get HOOQ at P199 per month

According to a Nielsen report in 2014, viewing online video content has become a pastime for digital consumers in the Philippines, with 85% watching at least weekly, the second highest in the region. The same report also revealed that 7 in 10 digital consumers in the country report watching TV content and movies via online sources such as video-on-demand, the second highest penetration of internet TV in the region at 71%.

“Now more than ever, Filipinos consider connectivity as an essential part of their daily lives. Our customers, whether prepaid, postpaid, or broadband, are increasingly embracing an always-on world where they expect a wonderful experience from innovative and engaging data and content offers. Right now, we are in the best position to offer this type of service as the leader in enabling the digital lifestyle of Filipinos and the number one network for smartphones. To meet their needs, we see the video-on-demand services offered by HOOQ as a critical offering representing the future of the industry. Now that consumers have access to a variety of international and local content, entertainment will now be more personal, and with Globe, this means experiencing it with the highest quality,” said Mr. Ernest Cu, President and CEO of Globe Telecom. 

Recognising the value that video-on-demand services deliver to consumers, Globe Telecom will provide its customers with the ability to download HOOQ, which will soon be available to customers on a plan-based service for Philippine Peso 199 per month for access to thousands of movies, far more affordable than buying a ticket for just one movie. It will also be offered as a bundled service with the telco’s GoSURF and Tattoo broadband services.

HOOQ enhances digital lifestyles

“Following the launch in the Philippines, HOOQ will be rolled out across Asia soon. The rapid adoption of connected devices means more people in Asia are able to access the Internet anywhere and at any time, driving demand for compelling content that enhances their digital lives,” said Mr Jonathan Auerbach, Singtel CEO Group Digital Life. “HOOQ is set to change the way people across the region consume and enjoy entertainment.”

Mr. George Chien, Executive Vice President, Networks at Sony Pictures Television, said: “We share the excitement of offering entertainment fans across Asia access to high quality video services directly to their mobile devices. HOOQ provides a unique combination of Hollywood and local favorites while providing a high-quality viewing experience they’ve come to expect in today’s digital world.”

Mr. Anuraj Goonetilleke, Vice President Corporate Business Development and Strategy at Warner Bros. Digital Distribution said: “We’re very excited about the launch of our joint video-on-demand business across Asia, starting with the Philippines.  Providing world-class content to Asia’s entertainment fans will meet a voracious appetite for new and classic videos and TV episodes on-demand.”

The service will also be accessible to all customers in the Philippines through its website — Through, customers can watch videos of their choice and pay for the subscription by credit card.

About HOOQ
HOOQ is a regional video-on-demand subscription service by Singtel, Sony and Warner Bros. HOOQ will deliver over 10,000 Hollywood blockbusters and popular local programmes to customers anytime, anywhere by enabling them to stream and download their favourite shows on their device or platform of choice. For more information, visit

About Globe Telecom
Globe Telecom is a leading full service telecommunications company in the Philippines, serving the needs of consumers and businesses across an entire suite of products and services including mobile, fixed, broadband, data connections, internet and managed services.  Its principals are Ayala Corporation and Singtel who are acknowledged industry leaders in the country and in the region.  For more information, visit  Follow Globe Telecom on Facebook at and Tatoo at as well as on Twitter @enjoyglobe and @choosetattoo and Instagram at @enjoyglobe and @choosetattoo.

About Singtel
Singtel is Asia’s leading communications group providing a portfolio of services including voice and data solutions over fixed, wireless and Internet platforms as well as infocomm technology and pay TV. The Group has presence in Asia and Africa with over 500 million mobile customers in 25 countries, including Bangladesh, India, Indonesia, the Philippines and Thailand. It also has a vast network of offices throughout Asia Pacific, Europe and the United States.

About Sony Pictures Entertainment
Sony Pictures Entertainment (SPE) is a subsidiary of Sony Entertainment Inc., a subsidiary of Tokyo-based Sony Corporation. SPE’s global operations encompass motion picture production, acquisition and distribution; television production, acquisition and distribution; television networks; digital content creation and distribution; operation of studio facilities; and development of new entertainment products, services and technologies. For additional information, go to

About Warner Bros. Entertainment
Warner Bros. Entertainment Inc. is a global leader in all forms of entertainment and their related businesses across all current and emerging media and platforms. A Time Warner Company, the fully integrated, broad-based studio is home to one of the most successful collections of brands in the world and stands at the forefront of every aspect of the entertainment industry from feature film, television and home entertainment production and worldwide distribution to DVD, digital distribution, animation, comic books, video games, product and brand licensing, and broadcasting.

Photo –

Exclusive Calvin Harris Partnership Crowns Hakkasan Group Global Investment Strategy

LONDON, Jan. 27, 2015 /PRNewswire/ — Global hospitality company Hakkasan Group, today announced a three-year partnership with award winning international DJ and recording artist Calvin Harris. The innovative partnership is the latest phase of an ambitious global investment strategy by Hakkasan Group to drive rapid growth while maintaining world-class experiences for its guests.


The collaboration will involve Harris working across Hakkasan Group’s wide portfolio of brands, drawing on his talents as a DJ, writer and producer. In particular, Harris has agreed to play exclusively at Hakkasan Group venues in Las Vegas for the next three years as well as to work collaboratively with Hakkasan Group to create unique experiences for its guests. In addition to his residency deals, Harris will act as a music consultant for the group’s renowned Hakkasan brand, refining and curating its global sound as it moves from restaurants and nightclubs into the hotel space. He will also be working closely with the senior team at Hakkasan Group to develop entirely new experiences and event concepts to bring to the ideas to life for guests and fans to experience.

The deal is a part of the Group’s ‘brand-first’ philosophy centred on creating consistent, world-class experiences that push the boundaries of hospitality. Commitment to brand and talent development is at the heart of the Hakkasan Group business strategy.

Hakkasan Group has enjoyed explosive growth with revenues increasing from $100 milllion to $500 million in less than two years. Key to this has been its ambitious expansion plans with a steady stream of new venues opening in the U.S., Middle East and Asia including a project to renovate PURE Nightclub at Caesars in Las Vegas, to reopen as Omnia. These exciting plans will continue in 2015 with 15 new venues slated to open in the coming year.

Recent investments also include the formation of a new hotel management company, MGM Hakkasan Hospitality, with MGM Resorts International. As part of this joint venture Hakkasan is building a 200 room boutique hotel on the Palm in Dubai. The hotel, due to open in 2017 will be truly world class, offering an unrivalled mix of luxury hospitality, food and nightlife.

Neil Moffitt, CEO of Hakkasan Group, commented: “Calvin Harris’ dedication, passion and creativity echo Hakkasan Group’s approach to business so it’s the perfect partnership for us. I have been involved in electronic music for many years now, so on a personal level it is hugely exciting to work with the leading international DJ talents. On a professional level, today’s announcement is important in what it says about our Group: that we are committed to creating unbeatable experiences for our guests.”

Calvin Harris commented: “Hakkasan Group’s heritage in part goes right back to the ’90s golden era of dance music and I am excited to be able to play a part in this next chapter of its story. Its venues are some of the best in the world for dance music and the opportunity to be part of the wider group as it develops into other markets and sectors is a really exciting prospect for me as an artist. We have some great ideas up our sleeves.”

Calvin Harris sits alongside Hakkasan Group’s stable of internationally recognised entertainment and hospitality professionals including: Executive Head Chef Tong Chee Hwee, who has led the Hakkasan kitchen since its inception and has achieved Michelin stars across multiple restaurants in the Group, and International Executive Chef Ho Chee Boon, a renowned Michelin-starred chef with 24 years’ experience.


Hakkasan Group is a worldwide entertainment, dining, nightlife, and hospitality company with establishments currently located across the United States, Europe, Middle East, and Asia. Its namesake is taken from its Michelin-star restaurant that set the high-level standard for the group’s collection of diverse brands. Its ‘brand-first’ philosophy builds dining, nightlife, day life, and soon-to-be hotel concepts into world-class lifestyle hospitality brands, all with a focus on service, design, innovation, and experience.

Its restaurant portfolio includes the flagship Hakkasan Restaurant with 12 locations worldwide, as well as Yauatcha, HKK, Sake no Hana, Herringbone, Searsucker, and Social House. Under the nightlife/daylife umbrella of brands are Hakkasan Nightclub, Wet Republic, HQ Nightclub, HQ Beach Club, Bootsy Bellows, Hooray Henry’s, THE NICE GUY, SHOREbar and Omnia (opening in Las Vegas and in San Diego, Spring 2015). In 2014, Hakkasan Group and MGM Resorts International announced the formation of a joint venture hotel management company named MGM Hakkasan Hospitality with a series of hotel and resort projects already under development including MGM projects in the Americas, the Middle East, and Asia along with Hakkasan projects in Abu Dhabi and Dubai. Hakkasan Group is owned by Tasameem Real Estate LLC, an Abu Dhabi-based investment company. For more information, visit


Scottish producer, DJ and song-writer Calvin Harris stands as the figurehead for modern dance music, having broken world records and dominated global music charts with his hits. As one of the most successful artists of all time, Calvin Harris has collaborated with global stars including Rihanna, Florence and The Machine, Gwen Stefani, Ellie Goulding, HAIM and Big Sean, and his fourth studio album ‘Motion’ is out now.


Jackie Oribello
Global Director of Public Relations, Hakkasan Group
T +44(0)20-7297-8965